

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030

CIN: L24239MH1924PLC001151

Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

Web: <a href="www.gsk-india.com">www.gsk-india.com</a>
Email: <a href="mailto:askus@gsk.com">askus@gsk.com</a>

3<sup>rd</sup> January 2024

To,

## **BSE LIMITED**

Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

## THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

## Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Hon'ble Delhi High Court has pronounced a judgement in favour of the Company dated 26<sup>th</sup> December 2023 pertaining to a pricing matter under the erstwhile DPCO 1995. The relevant details to be is disclosed is as under:

Sr no	Particulars	Details
1	Name of the judicial forum	Hon'ble Delhi High Court
2	Nature and details of the judgement	Hon'ble Court has quashed and set aside the demand of the National Pharmaceutical Pricing Authority (NPPA) raised on the Company vide its letters dated 5 <sup>th</sup> October 2004 and 17 <sup>th</sup> December 2004 respectively. Hon'ble Court has also directed that the Company would be entitled to the refund of the amount deposited along with any interest accrued thereon (Please see amounts in #5 below). The Court has also ordered that the bank guarantee as furnished by the Company vide the previous interim Order of the Hon'ble Court be refunded back to the Company.
3	Date of receipt of the judgement	26 <sup>th</sup> December, 2023[**].  ** Order was uploaded on the Delhi High Court website on 26 <sup>th</sup> December, 2023 and the same was downloaded by the Company on 2 <sup>nd</sup> January, 2024.
4	Details of violation(s) / contravention(s) committed or alleged to be committed	NIL
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	<ol> <li>Rs.4,35,46,347 (Already deposited with NPPA as per the previous interim Order of the Hon'ble Delhi High Court).</li> <li>Rs. 1,23,86,559 (maintained as bank guarantee with NPPA).</li> </ol>

Kindly take the same on the record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited